S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities

Phreesia Stock Price, News & Analysis (NYSE:PHR)

$18.03
+0.16 (+0.90%)
(As of 12/8/2023 ET)
Compare
Today's Range
$17.49
$18.25
50-Day Range
$12.40
$18.89
52-Week Range
$12.05
$40.00
Volume
836,082 shs
Average Volume
657,913 shs
Market Capitalization
$1.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.31

Phreesia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
90.3% Upside
$34.31 Price Target
Short Interest
Healthy
3.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.09mentions of Phreesia in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$567,877 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.54) to ($1.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

46th out of 946 stocks

Business Services, Not Elsewhere Classified Industry

8th out of 81 stocks


PHR stock logo

About Phreesia Stock (NYSE:PHR)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Wilmington, Delaware.

PHR Stock Price History

PHR Stock News Headlines

Phreesia (NYSE:PHR) Given New $30.00 Price Target at KeyCorp
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Phreesia (NYSE:PHR) Given New $25.00 Price Target at Raymond James
Is Phreesia Finally Turning The Corner?
Phreesia (NYSE:PHR) Shares Gap Up on Better-Than-Expected Earnings
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Phreesia Announces Third Quarter Fiscal 2024 Results
Where Phreesia Stands With Analysts
Q3 2024 Phreesia Inc Earnings Call
Recap: Phreesia Q3 Earnings
Phreesia Q3 2024 Earnings Preview
Phreesia earnings preview: what Wall Street is expecting
Earnings Preview For Phreesia
Here’s Why Phreesia (PHR) Declined in Q3
Phreesia Inc PHR
Vacancy rates remain high for Triangle office supply
See More Headlines
Receive PHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/06/2023
Today
12/08/2023
Fiscal Year End
1/31/2024
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Employees
1,546
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.31
High Stock Price Target
$43.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+90.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-176,150,000.00
Pretax Margin
-47.44%

Debt

Sales & Book Value

Annual Sales
$280.91 million
Book Value
$5.46 per share

Miscellaneous

Free Float
52,007,000
Market Cap
$995.44 million
Optionable
Not Optionable
Beta
0.84
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














PHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Phreesia stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHR shares.
View PHR analyst ratings
or view top-rated stocks.

What is Phreesia's stock price target for 2024?

13 brokerages have issued 12-month price targets for Phreesia's shares. Their PHR share price targets range from $25.00 to $43.00. On average, they anticipate the company's stock price to reach $34.31 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price.
View analysts price targets for PHR
or view top-rated stocks among Wall Street analysts.

How have PHR shares performed in 2023?

Phreesia's stock was trading at $32.36 at the beginning of the year. Since then, PHR shares have decreased by 44.3% and is now trading at $18.03.
View the best growth stocks for 2023 here
.

When is Phreesia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our PHR earnings forecast
.

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) posted its earnings results on Wednesday, December, 6th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business earned $91.62 million during the quarter, compared to the consensus estimate of $89.60 million. Phreesia had a negative trailing twelve-month return on equity of 54.28% and a negative net margin of 42.70%. The firm's revenue was up 25.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.76) earnings per share.

What ETFs hold Phreesia's stock?
What is Chaim Indig's approval rating as Phreesia's CEO?

172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA).

When did Phreesia IPO?

(PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Phreesia's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.23%), Brown Advisory Inc. (5.86%), Jennison Associates LLC (4.05%), Rock Springs Capital Management LP (3.22%), Riverbridge Partners LLC (1.56%) and Loomis Sayles & Co. L P (1.48%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, Cheryl Pegus, David Linetsky, Edward L Cahill, Edward L Cahill, Evan Roberts, Gillian Munson, Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, Randy Rasmussen and Thomas Altier.
View institutional ownership trends
.

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:PHR) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -